Achaogen

Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterials to treat multi-drug resistant (MDR), gram-negative infections.
Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including CRE.
Achaogen is developing an oral antibacterial candidate, C-Scape, a combination of an approved beta-lactam and an approved beta-lactamase inhibitor with the potential to treat patients with complicated urinary tract infections (cUTI) due to MDR pathogens.
The Company's research and development pipeline includes additional gram-negative programs such as inhibitors of LpxC, an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program.

Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
2004
Size (employees)
62 (est)
Achaogen was founded in 2004 and is headquartered in South San Francisco, US

Achaogen Office Locations

Achaogen has an office in South San Francisco
South San Francisco, US (HQ)
1 Tower Pl

Achaogen Data and Metrics

Achaogen Financial Metrics

Achaogen's revenue was reported to be $41.8 m in FY, 2016 which is a 60% increase from the previous period.
$, USD

Revenue (FY, 2016)

41.8 m

Revenue growth (FY, 2015 - FY, 2016), %

60%

Net income (FY, 2016)

(71.2 m)

EBIT (FY, 2016)

(49.3 m)

Market capitalization (22-Jun-2017)

806.3 m

Closing share price (22-Jun-2017)

23.4

Cash (31-Dec-2016)

119 m
Achaogen's current market capitalization is $806.3 m.
$, USDFY, 2014FY, 2015FY, 2016

Revenue

20 m26.1 m41.8 m

Revenue growth, %

31%60%

R&D expense

30.1 m40.2 m74 m

General and administrative expense

9.6 m12.4 m17.1 m

Operating expense total

39.8 m52.6 m91.1 m

EBIT

(19.8 m)(26.6 m)(49.3 m)

EBIT margin, %

(99%)(102%)(118%)

Interest expense

(397 k)(699 k)(2.3 m)

Net Income

(20.2 m)(27.1 m)(71.2 m)
$, USDFY, 2014FY, 2015FY, 2016

Cash

18.9 m20.3 m119 m

Accounts Receivable

301 k

Inventories

210.1 m

Current Assets

69.4 m65.5 m160.3 m

PP&E

725 k905 k3.3 m

Total Assets

70.3 m66.9 m163.9 m

Accounts Payable

2.1 m3.5 m5.7 m

Current Liabilities

5.5 m8.7 m19.7 m

Additional Paid-in Capital

213.5 m219.2 m353.9 m

Retained Earnings

(148.9 m)(176 m)(247.2 m)

Total Equity

43.2 m106.7 m

Financial Leverage

1.5 x1.5 x
$, USDFY, 2014FY, 2015FY, 2016

Net Income

(20.2 m)(27.1 m)(71.2 m)

Depreciation and Amortization

358 k426 k441 k

Cash From Operating Activities

8.1 m1.4 m(46.9 m)

Purchases of PP&E

(340 k)(606 k)(901 k)

Cash From Investing Activities

(45.4 m)5.2 m10.4 m

Cash From Financing Activities

67.9 m17.3 m135.5 m

Interest Paid

221 k396 k1.6 m
Y, 2016

Financial Leverage

1.5 x

Achaogen Market Value History

Achaogen Online and Social Media Presence

Achaogen Company Life and Culture

You may also be interested in